City Hill Ventures — Full Portfolio
2 tracked investments · listed companies and verified rows first
Erasca is a clinical-stage oncology company developing therapies targeting RAS- and MAPK pathway-driven cancers using a modality-agnostic approach including small molecules, large molecules, and protein degraders.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Jonathan E. Lim, M.D.(Chairman, CEO and Co-founder)Gary Yeung, CFA(Chief Business Officer)in
BoardAlexander W. Casdin(Director)Pratik S. Multani, M.D.(Director)Valerie Harding-Start(Director)James A. Bristol, Ph.D.(Director)
Co-investorsAndreessen HorowitzARCH Venture PartnersEvolution VC PartnersFrazier Life SciencesColt VenturesLifeSci Venture Partners
BiotechPhoenix, US
Douglas Grant McFadden, Ph.D.(Director)Steven J. Potts, Ph.D.(President and Chief Executive Officer)Ting Xiao(Director)Jason Rushton(Director)Kanad Das, Ph.D.(Director)Michael G. Wood(Executive Officer)
Co-investorsB Capital GroupBoehringer Ingelheim Venture FundDelos CapitalKorea Investment PartnersLumira VenturesLYZZ Capital+1 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.